Novartis broke ground on a 46,000-sq.-ft. radioligand therapy (RLT) manufacturing site in Denton Texas, its first in the state and fifth nationwide. Part of a $23 billion U.S. investment, the facility will enhance cancer treatment access and create jobs, strengthening Novartis’ nationwide RLT network and U.S.supply chain by 2028.